A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
Clinical trial NCT04288089 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04288089
- Sponsor
- Eisai Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-01
- Primary completion
- 2022-09-16
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.